iStar Medical announced the expansion of its commercial rollout of its MIGS implant MINIject® to the UK.
iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients today, recently announced it has further expanded its commercial rollout for MINIject® to the UK.
According to a press release, MINIject® is iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) implant, and is currently the only commercially available supraciliary MIGS device. It is designed to enhance natural fluid outflow, reduce intraocular pressure (IOP) and the need for medication, while bio-integrating with surrounding tissue, limiting inflammation, fibrosis and subsequent complications.
This expansion allows patients in the UK living with open angle glaucoma the benefit of the implant, which has demonstrated “meaningful and sustained performance, combined with a favourable safety profile,” the release states.
The first implants with MINIject have been successfully completed at The Colchester Eye Centre of Excellence (US) by Dr Chrys Dimitriou, consultant ophthalmic surgeon in cataract and glaucoma and specialist in MIGS.
Glaucoma, the leading cause of irreversible blindness, affects around 100 million people worldwide and approximately 10 million in Europe alone, according to the release. It goes on to say that “MIGS represents the most promising and fastest-growing glaucoma therapy, due to its enhanced safety profile compared to traditional surgery.”1